0.00Open3.40Pre Close0 Volume0 Open Interest27.50Strike Price0.00Turnover0.00%IV-61.10%PremiumAug 16, 2024Expiry Date12.54Intrinsic Value100Multiplier-7DDays to Expiry0.00Extrinsic Value100Contract Size--Options Type--Delta--Gamma4.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
4D Molecular Therapeutics Stock Discussion
🌈 静待股价回落,长线标的,观察仓开仓目标价14.85
⭕ Regulation FD Disclosure.
On July 23, 2024, 4D Molecular Therapeutics, Inc. (the “Company”) reported that interim longest available follow up data from the Phase 1 Dose Expansion cohort, Phase 2 Dose Expansion cohort, and Phase 2 Population Extension cohort from its Phase 1/2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration are expected to be presented at a medical conference in Septemb...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$